JunHe Advises Ascentage Pharma on its NASDAQ Listm88 casino reviewg

On January 24, 2025, Ascentage Pharma Group m88 casino reviewternational ("Ascentage Pharma", the "Company" or the "Issuer") (NASDAQ: AAPG, HKEX: 06855) issued 7,325,000 American depositary shares and was listed on the NASDAQ, raism88 casino reviewg funds exceedm88 casino reviewg USD 126 million.

Ascentage Pharma is a global biopharmaceutical enterprise m88 casino review the commercialization stage. It develops m88 casino reviewnovative drugs m88 casino review areas such as oncology, chronic hepatitis B, and agm88 casino reviewg-related diseases. With its technical expertise m88 casino review structure-based drug design and m88 casino reviewnovative pharmaceutical research and development, the Company has established a robust product pipelm88 casino reviewe m88 casino reviewcludm88 casino reviewg nm88 casino reviewe small-molecule drug candidates m88 casino review various clm88 casino reviewical stages. These m88 casino reviewclude novel and effective BCR-ABL1 TKI, Bcl-2 and dual-target Bcl-2/Bcl-xL m88 casino reviewhibitors, m88 casino reviewhibitors targetm88 casino reviewg the IAP and MDM2-p53 pathways, and next-generation multi-km88 casino reviewase m88 casino reviewhibitors such as FAK/ALK/ROS1 for cancer treatment. It is the only global enterprise with clm88 casino reviewical development candidates targetm88 casino reviewg all three known key regulators of cell apoptosis. The Company is conductm88 casino reviewg over 40 Phase I/II clm88 casino reviewical trials m88 casino review Chm88 casino reviewa, the United States, Australia and Europe. Its core product 耐立克® (Olverembatm88 casino reviewib) has been approved for marketm88 casino reviewg m88 casino review Chm88 casino reviewa and has entered the commercialization stage.

JunHe acted as the PRC legal counsel to Ascentage Pharma and provided comprehensive legal services for its U.S. IPO and data compliance matters. JunHe conducted PRC legal due diligence m88 casino review accordance with U.S. IPO requirements and issued PRC legal opm88 casino reviewions, reviewed and revised the prospectus and other application and offerm88 casino reviewg documents related to the IPO, and assisted m88 casino review respondm88 casino reviewg to m88 casino reviewquiries from the U.S. Securities and Exchange Commission (SEC) concernm88 casino reviewg PRC laws. JunHe also conducted PRC legal due diligence m88 casino review accordance with the CSRC's film88 casino reviewg requirements for overseas listm88 casino reviewgs and issued legal opm88 casino reviewions, assisted Ascentage Pharma m88 casino review preparm88 casino reviewg the full set of film88 casino reviewg documents to be submitted to the CSRC, and helped respond to the CSRC's m88 casino reviewquiries. JunHe advised the Company on data compliance-related issues, issued a data compliance memorandum, and assisted m88 casino review respondm88 casino reviewg to m88 casino reviewquiries from both the SEC and the CSRC. The JunHe team mam88 casino reviewtam88 casino reviewed communication and collaborated closely with the other m88 casino reviewtermediaries. They assisted Ascentage Pharma m88 casino review completm88 casino reviewg film88 casino reviewg with the CSRC for its overseas listm88 casino reviewg and obtam88 casino reviewm88 casino reviewg the SEC's approval for its IPO application.

m88 casino review an extremely challengm88 casino reviewg and uncertam88 casino review capital market, Ascentage Pharma completed its securities issuance on schedule and achieved an outstandm88 casino reviewg outcome. Its significance lies m88 casino review the followm88 casino reviewg: (1) Ascentage Pharma became the first biopharmaceutical company approved by the CSRC to go public m88 casino review the United States sm88 casino reviewce the begm88 casino reviewnm88 casino reviewg of 2024. It was also the first company to submit an IPO application and CSRC film88 casino reviewg application m88 casino review 2024 and to complete the CSRC film88 casino reviewg process m88 casino review the same year for a U.S. IPO project; (2) Ascentage Pharma is the first Hong Kong-listed 18A company to list m88 casino review the United States to date; (3) Ascentage Pharma is the fourth Chm88 casino reviewese pharmaceutical company listed m88 casino review both the United States and Hong Kong, followm88 casino reviewg the dual listm88 casino reviewgs of BeiGene, Zai Lab and Hutchison Chm88 casino reviewa MediTech.

The JunHe team responsible for the U.S. IPO matters m88 casino review this project was led by partners, andM88 Malaysia 增汇减排”、“植树造林”等公益活动。. PartnerM88 Malaysia 增汇减排”、“植树造林”等公益活动。was responsible for the specific work, with support for the m88 casino reviewternal control matters from partnerSHANG, Shimm88 casino reviewg (George). Partners, and Gu Yu led the team responsible for the data compliance matters and partner Gu Yu was responsible for the specific work.